Photo: Getty Images
Senator John Fetterman of Pennsylvania is calling on the Trump Administration to reconsider its decision to halt a rule that would allow Medicare and Medicaid to cover anti-obesity drugs. In a New York Times op-ed, Fetterman shared his personal experience with Mounjaro, a medication he credits with improving his health after a stroke in 2022. He emphasized the drug's significant impact, stating, "Aches, pains, and stiffness have vanished. Physically, I feel a decade younger."
The Biden Administration had proposed a rule to expand coverage for these drugs, which could benefit approximately 3.4 million Medicare users and 4 million Medicaid enrollees. However, the Centers for Medicare and Medicaid Services recently decided not to finalize the rule, citing no further details. Without insurance, these medications can cost up to $1,000 monthly.
Fetterman argues that expanding coverage is not just about weight loss but about improving overall health and reducing chronic disease costs, which exceed $1 trillion annually. He acknowledges the importance of diet and lifestyle changes but insists that medication can be a crucial first step for many Americans.
In his op-ed, Fetterman also addressed criticisms from Health and Human Services Secretary Robert F. Kennedy Jr., who advocates for prioritizing healthier diets. Fetterman believes that bipartisan support is essential for making these medications accessible and affordable, urging the Trump Administration to reverse its decision.